董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lon Cardon | 男 | Director | 57 | 44.24万美元 | 未持股 | 2023-05-01 |
| Niall O'Donnell | 男 | Director | 50 | 33.95万美元 | 未持股 | 2023-05-01 |
| Lon Cardon | 男 | Director | 57 | 未披露 | 未持股 | 2023-05-01 |
| William Fairey | 男 | Director | 59 | 26.25万美元 | 未持股 | 2023-05-01 |
| Timothy Walbert | 男 | Director | 56 | 未披露 | 未持股 | 2023-05-01 |
| Saira Ramasastry | 女 | Director | 47 | 未披露 | 未持股 | 2023-05-01 |
| Michael Grey | 男 | Chairman of the Board | 70 | 38.20万美元 | 未持股 | 2023-05-01 |
| Laura Brege | 女 | Director | 65 | 未披露 | 未持股 | 2023-05-01 |
| Saira Ramasastry | 女 | Director | 47 | 59.76万美元 | 未持股 | 2023-05-01 |
| Laurent Fischer | 男 | Director | 59 | 68.57万美元 | 未持股 | 2023-05-01 |
| Christopher Peetz | 男 | President and Chief Executive Officer and Director | 44 | 440.27万美元 | 未持股 | 2023-05-01 |
| Patrick Heron | 男 | Director | 52 | 33.14万美元 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Radovich | 男 | Chief Operating Officer | 45 | 156.14万美元 | 未持股 | 2023-05-01 |
| Pamela Vig | 女 | Head of Research and Development | 52 | 150.75万美元 | 未持股 | 2023-05-01 |
| Lara Longpre | 女 | Chief Development Officer | 53 | 150.75万美元 | 未持股 | 2023-05-01 |
| Peter Radovich | 男 | Chief Operating Officer | 45 | 未披露 | 未持股 | 2023-05-01 |
| Christopher Peetz | 男 | President and Chief Executive Officer and Director | 44 | 440.27万美元 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- Lon Cardon
-
Lon Cardon自2019年1月起担任我们的董事会成员。卡登博士曾担任Biomarin PharmaceuticalInc.的首席科学官。BioMarin，生物制药公司，自2017年9月起。在加入BioMarin之前，Cardon博士于2008年至2017年9月担任全球梦百合公司GlaxoSmithKline plc的遗传学，替代药物发现和目标科学高级副总裁。Cardon博士此前曾担任牛津大学（University of Oxford）的教授，以及华盛顿大学（University of Washington）和弗雷德·哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center）的生物统计学和人类生物学教授。Cardon博士是NIH/National Human Genome Research Institute的前理事会成员，也是All US Precision Medicine Initiative的现任顾问。Cardon博士担任Altius Institute for Biomedical Sciences，Centre for Therapeutic Target Validation（现为Open Targets）和GSK/Avalon卓越中心的董事会成员和机构创始人。卡登博士是英国医学科学院和美国科学促进会的当选院士。Cardon博士在普吉特海湾大学（University of Puget Sound）获得心理学/生物学学士学位，在科罗拉多大学博尔德分校（University of Colorado，Boulder）获得博士学位，并在斯坦福大学（Stanford University）进行博士后培训。
Lon Cardon,has served as a member of Mirum Pharmaceuticals, Inc. board of directors since November, 2022. Dr. Cardon has served as President and Chief Executive Officer at The Jackson Laboratory, an independent, nonprofit biomedical research organization, since November, 2021. Prior to joining The Jackson Laboratory, Dr. Cardon served as Chief Scientific Officer at BioMarin Pharmaceutical Inc., a biopharmaceutical company, from September 2017 to November 2021. Prior to joining BioMarin, Dr. Cardon served as Senior Vice President of Genetics, Alternative Drug Discovery and Target Sciences at GlaxoSmithKline plc, a global healthcare company, from 2008 to September 2017. Dr. Cardon previously served as a professor at the University of Oxford and as a professor of biostatistics and human biology at the University of Washington and the Fred Hutchinson Cancer Research Center. Dr. Cardon is a past council member of the NIH/National Human Genome Research Institute and a present advisor to the All of Mirum Pharmaceuticals, Inc. Precision Medicine Initiative. Dr. Cardon served as a member of the board of directors and institutional founder of the Altius Institute for Biomedical Sciences, Centre for Therapeutic Target Validation (now Open Targets) and the GSK/Avalon Center of Excellence. Dr. Cardon is an elected fellow of the UK's Academy of Medical Sciences and the American Association for the Advancement of Science. Dr. Cardon received his B.S. in Psychology/Biology from the University of Puget Sound, a Ph.D. from the University of Colorado, Boulder and did his postdoctoral training at Stanford University. - Lon Cardon自2019年1月起担任我们的董事会成员。卡登博士曾担任Biomarin PharmaceuticalInc.的首席科学官。BioMarin，生物制药公司，自2017年9月起。在加入BioMarin之前，Cardon博士于2008年至2017年9月担任全球梦百合公司GlaxoSmithKline plc的遗传学，替代药物发现和目标科学高级副总裁。Cardon博士此前曾担任牛津大学（University of Oxford）的教授，以及华盛顿大学（University of Washington）和弗雷德·哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center）的生物统计学和人类生物学教授。Cardon博士是NIH/National Human Genome Research Institute的前理事会成员，也是All US Precision Medicine Initiative的现任顾问。Cardon博士担任Altius Institute for Biomedical Sciences，Centre for Therapeutic Target Validation（现为Open Targets）和GSK/Avalon卓越中心的董事会成员和机构创始人。卡登博士是英国医学科学院和美国科学促进会的当选院士。Cardon博士在普吉特海湾大学（University of Puget Sound）获得心理学/生物学学士学位，在科罗拉多大学博尔德分校（University of Colorado，Boulder）获得博士学位，并在斯坦福大学（Stanford University）进行博士后培训。
- Lon Cardon,has served as a member of Mirum Pharmaceuticals, Inc. board of directors since November, 2022. Dr. Cardon has served as President and Chief Executive Officer at The Jackson Laboratory, an independent, nonprofit biomedical research organization, since November, 2021. Prior to joining The Jackson Laboratory, Dr. Cardon served as Chief Scientific Officer at BioMarin Pharmaceutical Inc., a biopharmaceutical company, from September 2017 to November 2021. Prior to joining BioMarin, Dr. Cardon served as Senior Vice President of Genetics, Alternative Drug Discovery and Target Sciences at GlaxoSmithKline plc, a global healthcare company, from 2008 to September 2017. Dr. Cardon previously served as a professor at the University of Oxford and as a professor of biostatistics and human biology at the University of Washington and the Fred Hutchinson Cancer Research Center. Dr. Cardon is a past council member of the NIH/National Human Genome Research Institute and a present advisor to the All of Mirum Pharmaceuticals, Inc. Precision Medicine Initiative. Dr. Cardon served as a member of the board of directors and institutional founder of the Altius Institute for Biomedical Sciences, Centre for Therapeutic Target Validation (now Open Targets) and the GSK/Avalon Center of Excellence. Dr. Cardon is an elected fellow of the UK's Academy of Medical Sciences and the American Association for the Advancement of Science. Dr. Cardon received his B.S. in Psychology/Biology from the University of Puget Sound, a Ph.D. from the University of Colorado, Boulder and did his postdoctoral training at Stanford University.
- Niall O'Donnell
-
Niall O’Donnell自2017年12月起担任我们的董事会成员。O’Donnell博士是我们的联合创始人，此前曾于2017年12月至2020年11月担任我们的总裁兼首席执行官。O’Donnell博士目前是Rivervest Venture Partners Rivervest（一家风险投资公司）的董事总经理，他从2014年4月开始担任该职位。他于2006年加入Rivervest公司，在那里他曾专注于生物制药、诊断和医疗设备机会，并为Rivervest附属投资组合公司的形成、发展和业务战略做出贡献。从2011年到2013年，O’Donnell博士担任旭光制药公司的代理首席临时医疗官，该公司是一家私人生物制药公司，在那里他领导了该公司临床战略的开发和执行，最终被Shire plc收购。从2019年2月至2020年4月，O’Donnell博士共同创立了私人制药公司Curzion Pharmaceuticals，Inc.，并担任其董事会成员。O’Donnell博士自2016年5月起担任上市生物技术公司SpruceBiosciences，Inc.的董事会成员，自2018年12月起担任上市生物制药公司MirumPharmaceuticals，Inc.的董事会成员，也是这些私人生物制药公司的董事会成员，Amplyx Pharmaceuticals，Inc.和Avalyn Pharma，Inc.O’Donnell博士在苏格兰邓迪大学（University of Dundee）获得生物化学博士学位，在牛津彭布罗克学院（Pembroke College，Oxford）获得生物化学硕士学位，在圣地亚哥加利福尼亚大学（University of California）雷迪管理学院（Rady School of Management）获得工商管理硕士学位。
Niall O'Donnell,has served as a member of the Board since November 2018. Dr. O'Donnell is currently a Managing Director at RiverVest Venture Partners, a venture capital firm, a position he has held since April 2014. He joined RiverVest Venture Partners in 2006 where he has focused on biopharmaceutical, diagnostic and medical device opportunities and contributes to the formation, development and business strategies of RiverVest Venture Partners portfolio companies. Dr. O'Donnell served as President and Chief and Executive Officer of Reneo Pharmaceuticals, Inc., a privately-held pharmaceutical company, which he co-founded, from December 2017 to November 2020. From 2011 to 2013, he served as acting chief interim medical officer at Lumena Pharmaceuticals, Inc., where he led the development and execution of the company's clinical strategy leading up to its acquisition by Shire plc. Dr. O'Donnell currently serves on the boards of directors of public biotechnology companies Spruce Biosciences, Inc. and Reneo Pharmaceuticals, Inc., as well as privately-held pharmaceutical companies Avalyn Pharma, Inc., Glycomine, Inc. and Sparrow Pharmaceuticals, Inc. Dr. O'Donnell received his Ph.D. in biochemistry from the University of Dundee, Scotland, an M.A. in biochemistry from Pembroke College, Oxford and an MBA from the Rady School of Management of the University of California, San Diego. - Niall O’Donnell自2017年12月起担任我们的董事会成员。O’Donnell博士是我们的联合创始人，此前曾于2017年12月至2020年11月担任我们的总裁兼首席执行官。O’Donnell博士目前是Rivervest Venture Partners Rivervest（一家风险投资公司）的董事总经理，他从2014年4月开始担任该职位。他于2006年加入Rivervest公司，在那里他曾专注于生物制药、诊断和医疗设备机会，并为Rivervest附属投资组合公司的形成、发展和业务战略做出贡献。从2011年到2013年，O’Donnell博士担任旭光制药公司的代理首席临时医疗官，该公司是一家私人生物制药公司，在那里他领导了该公司临床战略的开发和执行，最终被Shire plc收购。从2019年2月至2020年4月，O’Donnell博士共同创立了私人制药公司Curzion Pharmaceuticals，Inc.，并担任其董事会成员。O’Donnell博士自2016年5月起担任上市生物技术公司SpruceBiosciences，Inc.的董事会成员，自2018年12月起担任上市生物制药公司MirumPharmaceuticals，Inc.的董事会成员，也是这些私人生物制药公司的董事会成员，Amplyx Pharmaceuticals，Inc.和Avalyn Pharma，Inc.O’Donnell博士在苏格兰邓迪大学（University of Dundee）获得生物化学博士学位，在牛津彭布罗克学院（Pembroke College，Oxford）获得生物化学硕士学位，在圣地亚哥加利福尼亚大学（University of California）雷迪管理学院（Rady School of Management）获得工商管理硕士学位。
- Niall O'Donnell,has served as a member of the Board since November 2018. Dr. O'Donnell is currently a Managing Director at RiverVest Venture Partners, a venture capital firm, a position he has held since April 2014. He joined RiverVest Venture Partners in 2006 where he has focused on biopharmaceutical, diagnostic and medical device opportunities and contributes to the formation, development and business strategies of RiverVest Venture Partners portfolio companies. Dr. O'Donnell served as President and Chief and Executive Officer of Reneo Pharmaceuticals, Inc., a privately-held pharmaceutical company, which he co-founded, from December 2017 to November 2020. From 2011 to 2013, he served as acting chief interim medical officer at Lumena Pharmaceuticals, Inc., where he led the development and execution of the company's clinical strategy leading up to its acquisition by Shire plc. Dr. O'Donnell currently serves on the boards of directors of public biotechnology companies Spruce Biosciences, Inc. and Reneo Pharmaceuticals, Inc., as well as privately-held pharmaceutical companies Avalyn Pharma, Inc., Glycomine, Inc. and Sparrow Pharmaceuticals, Inc. Dr. O'Donnell received his Ph.D. in biochemistry from the University of Dundee, Scotland, an M.A. in biochemistry from Pembroke College, Oxford and an MBA from the Rady School of Management of the University of California, San Diego.
- Lon Cardon
-
Lon Cardon，自2022年11月起担任Mirum制药董事会成员。卡顿博士自2021年11月起担任杰克逊实验室的总裁兼首席执行官，该实验室是一家独立的非营利性生物医学研究组织。在加入杰克逊实验室之前，Cardon博士曾于2017年9月至2021年11月在生物制药公司BioMarin Pharmaceutical Inc.担任首席科学官。在加入BioMarin之前，Cardon博士曾于2008年至2017年9月在全球医疗保健公司葛兰素史克（GlaxoSmithKline plc）担任遗传学、替代药物发现和靶点科学高级副总裁。卡登博士此前曾担任牛津大学教授，华盛顿大学和弗雷德哈钦森癌症研究中心生物统计学和人类生物学教授。卡登博士是美国国立卫生研究院/国家人类基因组研究所的前任理事会成员，也是全美精准医学倡议的现任顾问。Cardon博士曾担任Altius生物医学科学研究所、治疗靶点验证中心（现为开放靶点）和GSK/Avalon卓越中心的董事会成员和机构创始人。卡登博士是英国医学科学院和美国科学促进会的当选院士。Cardon博士在普吉特海湾大学获得心理学/生物学学士学位，在科罗拉多大学博尔德分校获得博士学位，并在斯坦福大学进行博士后培训。
Lon Cardon,has served as a member of Mirum Pharmaceuticals, Inc. board of directors since November, 2022. Dr. Cardon has served as President and Chief Executive Officer at The Jackson Laboratory, an independent, nonprofit biomedical research organization, since November, 2021. Prior to joining The Jackson Laboratory, Dr. Cardon served as Chief Scientific Officer at BioMarin Pharmaceutical Inc., a biopharmaceutical company, from September 2017 to November 2021. Prior to joining BioMarin, Dr. Cardon served as Senior Vice President of Genetics, Alternative Drug Discovery and Target Sciences at GlaxoSmithKline plc, a global healthcare company, from 2008 to September 2017. Dr. Cardon previously served as a professor at the University of Oxford and as a professor of biostatistics and human biology at the University of Washington and the Fred Hutchinson Cancer Research Center. Dr. Cardon is a past council member of the NIH/National Human Genome Research Institute and a present advisor to the All of Mirum Pharmaceuticals, Inc. Precision Medicine Initiative. Dr. Cardon served as a member of the board of directors and institutional founder of the Altius Institute for Biomedical Sciences, Centre for Therapeutic Target Validation (now Open Targets) and the GSK/Avalon Center of Excellence. Dr. Cardon is an elected fellow of the UK's Academy of Medical Sciences and the American Association for the Advancement of Science. Dr. Cardon received his B.S. in Psychology/Biology from the University of Puget Sound, a Ph.D. from the University of Colorado, Boulder and did his postdoctoral training at Stanford University. - Lon Cardon，自2022年11月起担任Mirum制药董事会成员。卡顿博士自2021年11月起担任杰克逊实验室的总裁兼首席执行官，该实验室是一家独立的非营利性生物医学研究组织。在加入杰克逊实验室之前，Cardon博士曾于2017年9月至2021年11月在生物制药公司BioMarin Pharmaceutical Inc.担任首席科学官。在加入BioMarin之前，Cardon博士曾于2008年至2017年9月在全球医疗保健公司葛兰素史克（GlaxoSmithKline plc）担任遗传学、替代药物发现和靶点科学高级副总裁。卡登博士此前曾担任牛津大学教授，华盛顿大学和弗雷德哈钦森癌症研究中心生物统计学和人类生物学教授。卡登博士是美国国立卫生研究院/国家人类基因组研究所的前任理事会成员，也是全美精准医学倡议的现任顾问。Cardon博士曾担任Altius生物医学科学研究所、治疗靶点验证中心（现为开放靶点）和GSK/Avalon卓越中心的董事会成员和机构创始人。卡登博士是英国医学科学院和美国科学促进会的当选院士。Cardon博士在普吉特海湾大学获得心理学/生物学学士学位，在科罗拉多大学博尔德分校获得博士学位，并在斯坦福大学进行博士后培训。
- Lon Cardon,has served as a member of Mirum Pharmaceuticals, Inc. board of directors since November, 2022. Dr. Cardon has served as President and Chief Executive Officer at The Jackson Laboratory, an independent, nonprofit biomedical research organization, since November, 2021. Prior to joining The Jackson Laboratory, Dr. Cardon served as Chief Scientific Officer at BioMarin Pharmaceutical Inc., a biopharmaceutical company, from September 2017 to November 2021. Prior to joining BioMarin, Dr. Cardon served as Senior Vice President of Genetics, Alternative Drug Discovery and Target Sciences at GlaxoSmithKline plc, a global healthcare company, from 2008 to September 2017. Dr. Cardon previously served as a professor at the University of Oxford and as a professor of biostatistics and human biology at the University of Washington and the Fred Hutchinson Cancer Research Center. Dr. Cardon is a past council member of the NIH/National Human Genome Research Institute and a present advisor to the All of Mirum Pharmaceuticals, Inc. Precision Medicine Initiative. Dr. Cardon served as a member of the board of directors and institutional founder of the Altius Institute for Biomedical Sciences, Centre for Therapeutic Target Validation (now Open Targets) and the GSK/Avalon Center of Excellence. Dr. Cardon is an elected fellow of the UK's Academy of Medical Sciences and the American Association for the Advancement of Science. Dr. Cardon received his B.S. in Psychology/Biology from the University of Puget Sound, a Ph.D. from the University of Colorado, Boulder and did his postdoctoral training at Stanford University.
- William Fairey
-
William Fairey，自2021年起担任Mirum董事会成员。最近，从2019年1月到2020年11月，Fairey先生在生物制药公司MyoKardia，Inc.担任执行副总裁兼首席商务官，在那里他构建了商业和投资组合战略，建立了公司的欧洲总部，并在公司被百时美施贵宝收购时正在构建拉丁美洲和亚洲的扩张结构。在任职于MyoKardia之前，Fairey先生于2018年3月至2019年1月在生物制药公司ChemoCentryx公司担任执行副总裁兼首席运营官，负责销售、市场营销、医疗事务和市场准入职能，包括后期化合物的商业化。在加入ChemoCentryx之前，Fairey先生曾在Actelion Pharmaceuticals Ltd.及其子公司担任过多个职务，包括2013年4月至2017年12月担任制药和生物技术公司Actelion Pharmaceuticals US，Inc.总裁；2008年7月至2013年3月担任Actelion Pharmaceuticals Ltd.澳大利亚亚太地区区域副总裁；2003年6月至2008年6月担任Actelion Pharmaceuticals Canada Inc.总裁；2001年1月至2003年6月担任Actelion Pharmaceuticals US，Inc.销售和管理市场副总裁。Fairey先生目前在上市生物技术公司Ascendis制药，Inc.以及私营制药公司Lung Therapeutics，Inc.和Respira Therapeutics，Inc.的董事会任职。Fairey先生获得了俄勒冈大学的生物学学士学位和圣玛丽学院的工商管理硕士学位。
William Fairey,has served on Mirum's board of directors since 2021. Most recently, from January 2019 to November 2020, Mr. Fairey served as Executive Vice President and Chief Commercial Officer at MyoKardia, Inc., a biopharmaceutical company, where he built the commercial and portfolio strategy, established the company's European headquarters, and was structuring the expansion in Latin America and Asia when the company was acquired by Bristol-Myers Squibb. Prior to serving at MyoKardia, Mr. Fairey served as Executive Vice President and Chief Operating Officer at ChemoCentryx, Inc., a biopharmaceutical company, from March 2018 to January 2019, where, he was responsible for the sales, marketing, medical affairs and market access functions, including commercialization of late stages compounds. Prior to ChemoCentryx, Mr. Fairey served in a number of roles at Actelion Pharmaceuticals Ltd. and its subsidiaries including as President of Actelion Pharmaceuticals US, Inc., a pharmaceuticals and biotechnology company, from April 2013 to December 2017, Regional Vice President, Australia Asia Pacific, of Actelion Pharmaceuticals Ltd. from July 2008 to March 2013, President of Actelion Pharmaceuticals Canada Inc. from June 2003 to June 2008, and Vice President of Sales and Management Markets of Actelion Pharmaceuticals US, Inc. from January 2001 to June 2003. Mr. Fairey currently serves on the boards of directors of Ascendis Pharma, Inc., a public biotechnology company, as well as privately-held pharmaceutical companies Lung Therapeutics, Inc. and Respira Therapeutics, Inc. Mr. Fairey received his B.S. in biology from the University of Oregon and an M.B.A. from Saint Mary's College. - William Fairey，自2021年起担任Mirum董事会成员。最近，从2019年1月到2020年11月，Fairey先生在生物制药公司MyoKardia，Inc.担任执行副总裁兼首席商务官，在那里他构建了商业和投资组合战略，建立了公司的欧洲总部，并在公司被百时美施贵宝收购时正在构建拉丁美洲和亚洲的扩张结构。在任职于MyoKardia之前，Fairey先生于2018年3月至2019年1月在生物制药公司ChemoCentryx公司担任执行副总裁兼首席运营官，负责销售、市场营销、医疗事务和市场准入职能，包括后期化合物的商业化。在加入ChemoCentryx之前，Fairey先生曾在Actelion Pharmaceuticals Ltd.及其子公司担任过多个职务，包括2013年4月至2017年12月担任制药和生物技术公司Actelion Pharmaceuticals US，Inc.总裁；2008年7月至2013年3月担任Actelion Pharmaceuticals Ltd.澳大利亚亚太地区区域副总裁；2003年6月至2008年6月担任Actelion Pharmaceuticals Canada Inc.总裁；2001年1月至2003年6月担任Actelion Pharmaceuticals US，Inc.销售和管理市场副总裁。Fairey先生目前在上市生物技术公司Ascendis制药，Inc.以及私营制药公司Lung Therapeutics，Inc.和Respira Therapeutics，Inc.的董事会任职。Fairey先生获得了俄勒冈大学的生物学学士学位和圣玛丽学院的工商管理硕士学位。
- William Fairey,has served on Mirum's board of directors since 2021. Most recently, from January 2019 to November 2020, Mr. Fairey served as Executive Vice President and Chief Commercial Officer at MyoKardia, Inc., a biopharmaceutical company, where he built the commercial and portfolio strategy, established the company's European headquarters, and was structuring the expansion in Latin America and Asia when the company was acquired by Bristol-Myers Squibb. Prior to serving at MyoKardia, Mr. Fairey served as Executive Vice President and Chief Operating Officer at ChemoCentryx, Inc., a biopharmaceutical company, from March 2018 to January 2019, where, he was responsible for the sales, marketing, medical affairs and market access functions, including commercialization of late stages compounds. Prior to ChemoCentryx, Mr. Fairey served in a number of roles at Actelion Pharmaceuticals Ltd. and its subsidiaries including as President of Actelion Pharmaceuticals US, Inc., a pharmaceuticals and biotechnology company, from April 2013 to December 2017, Regional Vice President, Australia Asia Pacific, of Actelion Pharmaceuticals Ltd. from July 2008 to March 2013, President of Actelion Pharmaceuticals Canada Inc. from June 2003 to June 2008, and Vice President of Sales and Management Markets of Actelion Pharmaceuticals US, Inc. from January 2001 to June 2003. Mr. Fairey currently serves on the boards of directors of Ascendis Pharma, Inc., a public biotechnology company, as well as privately-held pharmaceutical companies Lung Therapeutics, Inc. and Respira Therapeutics, Inc. Mr. Fairey received his B.S. in biology from the University of Oregon and an M.B.A. from Saint Mary's College.
- Timothy Walbert
-
Timothy Walbert，自2023年4月起担任董事会成员。沃尔伯特先生自2008年6月起担任上市生物制药公司Horizon Therapeutics PLC的总裁、首席执行官和董事，并自2010年3月起担任其董事长。2007年5月至2009年6月，沃尔伯特先生担任IDM Pharma，Inc.的总裁、首席执行官和董事，IDM Pharma，Inc.是一家上市生物技术公司，于2009年6月被Takeda America Holdings，Inc.收购。在此之前，他曾担任上市生物技术公司NeoPharm，Inc.的商业运营执行副总裁。2001年6月至2005年8月，Walbert先生担任部门副总裁兼免疫学总经理，在那里他建立并领导了多适应症生物制剂HUMIRA的全球开发和推出，并在雅培（现为艾伯维）担任部门副总裁，负责全球心血管战略。1998年至2001年，他在G.D. Searle & Company担任董事、CELEBREX北美和关节炎团队负责人、亚太、拉丁美洲和加拿大。沃尔伯特先生还担任上市生物技术公司Century Therapeutics, Inc.的董事会成员。沃尔伯特先生目前是伊利诺伊州生物技术创新组织（iBIO）的董事会成员。沃尔伯特先生还是国家罕见疾病组织（NORD）咨询委员会的成员，并在穆伦贝格学院董事会任职。他此前曾于2020年4月至2022年9月担任上市生物技术公司Aurinia制药，Inc.的董事会主席，2019年7月至2022年2月担任公共临床阶段生物技术公司Exicure, Inc.；2020年5月至2020年12月担任公共专业制药公司Assertio Holdings, Inc.（此前在上市制药公司Zyla Life Sciences任职，2014年4月至2020年5月被Assertio收购）；2016年至2018年担任公共生物制药公司Sucampo Pharmaceuticals, Inc.，当时其被万灵科收购。沃尔伯特先生在穆伦贝格学院获得商学学士学位。
Timothy Walbert,has served as a member of the Board since April 2023. Mr. Walbert has served as president, chief executive officer and director of Horizon Therapeutics plc, a public biopharmaceutical company, since June 2008 and as its chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert also serves on the board of Century Therapeutics, Inc., a public biotechnology company. Mr. Walbert currently sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Aurinia Pharmaceuticals, Inc., a public biotechnology company, from April 2020 to September 2022, Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his B.A. in business from Muhlenberg College. - Timothy Walbert，自2023年4月起担任董事会成员。沃尔伯特先生自2008年6月起担任上市生物制药公司Horizon Therapeutics PLC的总裁、首席执行官和董事，并自2010年3月起担任其董事长。2007年5月至2009年6月，沃尔伯特先生担任IDM Pharma，Inc.的总裁、首席执行官和董事，IDM Pharma，Inc.是一家上市生物技术公司，于2009年6月被Takeda America Holdings，Inc.收购。在此之前，他曾担任上市生物技术公司NeoPharm，Inc.的商业运营执行副总裁。2001年6月至2005年8月，Walbert先生担任部门副总裁兼免疫学总经理，在那里他建立并领导了多适应症生物制剂HUMIRA的全球开发和推出，并在雅培（现为艾伯维）担任部门副总裁，负责全球心血管战略。1998年至2001年，他在G.D. Searle & Company担任董事、CELEBREX北美和关节炎团队负责人、亚太、拉丁美洲和加拿大。沃尔伯特先生还担任上市生物技术公司Century Therapeutics, Inc.的董事会成员。沃尔伯特先生目前是伊利诺伊州生物技术创新组织（iBIO）的董事会成员。沃尔伯特先生还是国家罕见疾病组织（NORD）咨询委员会的成员，并在穆伦贝格学院董事会任职。他此前曾于2020年4月至2022年9月担任上市生物技术公司Aurinia制药，Inc.的董事会主席，2019年7月至2022年2月担任公共临床阶段生物技术公司Exicure, Inc.；2020年5月至2020年12月担任公共专业制药公司Assertio Holdings, Inc.（此前在上市制药公司Zyla Life Sciences任职，2014年4月至2020年5月被Assertio收购）；2016年至2018年担任公共生物制药公司Sucampo Pharmaceuticals, Inc.，当时其被万灵科收购。沃尔伯特先生在穆伦贝格学院获得商学学士学位。
- Timothy Walbert,has served as a member of the Board since April 2023. Mr. Walbert has served as president, chief executive officer and director of Horizon Therapeutics plc, a public biopharmaceutical company, since June 2008 and as its chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert also serves on the board of Century Therapeutics, Inc., a public biotechnology company. Mr. Walbert currently sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Aurinia Pharmaceuticals, Inc., a public biotechnology company, from April 2020 to September 2022, Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his B.A. in business from Muhlenberg College.
- Saira Ramasastry
-
Saira Ramasastry，自2022年6月起担任Mirum董事会成员。Ramasastry女士自2009年4月起担任Life Science Advisory，LLC的管理合伙人，该公司是她创立的一家独立公司，旨在为生命科学公司提供战略建议和业务发展解决方案。此前，Ramasastry女士曾于1999年8月至2009年3月在美林公司担任投资银行家，在那里她帮助建立了生物技术实践，并就并购、战略和资本市场交易提供咨询。在加入美林证券之前，Ramasastry女士曾于1997年7月至1998年9月在投资银行公司Wasserstein Perella & Co.担任并购集团的财务分析师。Ramasastry女士目前在Vir Biotechnology, Inc.、Glenmark Pharmaceuticals，Ltd.和Day One Biopharmaceuticals, Inc.的董事会任职，在管理网络安全风险方面拥有丰富的经验。Ramasastry女士还担任帕金森研究迈克尔·J·福克斯基金会的行业顾问委员会成员、阿斯彭研究所的健康创新者研究员以及阿斯彭全球领导力网络的成员。Ramsastry女士还是剑桥大学生物科学企业项目的客座讲师，并在美国剑桥的加州董事会任职。Ramasastry女士以优异的成绩获得了经济学学士学位，获得了斯坦福大学管理科学和工程硕士学位，并获得了剑桥大学管理学硕士学位。
Saira Ramasastry,has served on Mirum's Board of Directors since June 2022. Ms. Ramasastry has served as the managing partner of Life Science Advisory, LLC, an independent firm that she founded to provide strategic advice and business development solutions for life science companies, since April 2009. Previously, Ms. Ramasastry was an investment banker with Merrill Lynch & Company from August 1999 to March 2009, where she helped establish the biotechnology practice and advised on mergers and acquisitions and strategic and capital market transactions. Prior to joining Merrill Lynch, Ms. Ramasastry served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry currently serves on the board of directors for Vir Biotechnology, Inc., Glenmark Pharmaceuticals, Ltd. and Day One Biopharmaceuticals, Inc., where she has experience managing cybersecurity risks. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson's Research, as a health innovator fellow of the Aspen Institute and as a member of the Aspen Global Leadership Network. Ms. Ramsastry is also a guest lecturer for the Bioscience Enterprise Programme at University of Cambridge, and serves on the California board of Cambridge in America. Ms. Ramasastry received her B.A. in economics with honors and distinction and her M.S. in management science and engineering from Stanford University, as well as her M. Phil. in management studies from the University of Cambridge. - Saira Ramasastry，自2022年6月起担任Mirum董事会成员。Ramasastry女士自2009年4月起担任Life Science Advisory，LLC的管理合伙人，该公司是她创立的一家独立公司，旨在为生命科学公司提供战略建议和业务发展解决方案。此前，Ramasastry女士曾于1999年8月至2009年3月在美林公司担任投资银行家，在那里她帮助建立了生物技术实践，并就并购、战略和资本市场交易提供咨询。在加入美林证券之前，Ramasastry女士曾于1997年7月至1998年9月在投资银行公司Wasserstein Perella & Co.担任并购集团的财务分析师。Ramasastry女士目前在Vir Biotechnology, Inc.、Glenmark Pharmaceuticals，Ltd.和Day One Biopharmaceuticals, Inc.的董事会任职，在管理网络安全风险方面拥有丰富的经验。Ramasastry女士还担任帕金森研究迈克尔·J·福克斯基金会的行业顾问委员会成员、阿斯彭研究所的健康创新者研究员以及阿斯彭全球领导力网络的成员。Ramsastry女士还是剑桥大学生物科学企业项目的客座讲师，并在美国剑桥的加州董事会任职。Ramasastry女士以优异的成绩获得了经济学学士学位，获得了斯坦福大学管理科学和工程硕士学位，并获得了剑桥大学管理学硕士学位。
- Saira Ramasastry,has served on Mirum's Board of Directors since June 2022. Ms. Ramasastry has served as the managing partner of Life Science Advisory, LLC, an independent firm that she founded to provide strategic advice and business development solutions for life science companies, since April 2009. Previously, Ms. Ramasastry was an investment banker with Merrill Lynch & Company from August 1999 to March 2009, where she helped establish the biotechnology practice and advised on mergers and acquisitions and strategic and capital market transactions. Prior to joining Merrill Lynch, Ms. Ramasastry served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry currently serves on the board of directors for Vir Biotechnology, Inc., Glenmark Pharmaceuticals, Ltd. and Day One Biopharmaceuticals, Inc., where she has experience managing cybersecurity risks. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson's Research, as a health innovator fellow of the Aspen Institute and as a member of the Aspen Global Leadership Network. Ms. Ramsastry is also a guest lecturer for the Bioscience Enterprise Programme at University of Cambridge, and serves on the California board of Cambridge in America. Ms. Ramasastry received her B.A. in economics with honors and distinction and her M.S. in management science and engineering from Stanford University, as well as her M. Phil. in management studies from the University of Cambridge.
- Michael Grey
-
Michael Grey，自2017年4月起担任董事会执行主席，并于2021年11月至2022年1月担任Spruce Biosciences, Inc.临时首席执行官。此外，Grey先生自2020年1月起担任上市生物制药公司Mirum Pharmaceuticals, Inc.的董事长，并自2018年5月起担任Mirum的董事。Grey先生此前曾于2019年3月至2019年12月担任Mirum执行主席，并于2018年5月至2019年3月担任Mirum首席执行官。Grey先生于2017年12月至2024年10月担任Reneo Pharmaceuticals，Inc.（于2024年与生物制药公司OnKure，Inc.合并）的执行主席，并自2024年10月起担任OnKure的董事。Grey先生自2020年9月起担任Plexium执行董事长。他自2021年5月起担任私营制药公司Sorriso Pharmaceuticals，Inc.的董事长，并自2023年11月起担任私营生物技术公司Theolytics Ltd.的执行主席。Grey先生此前曾于2005年12月至2021年5月担任BioMarin的董事，并于2014年11月至2021年6月担任生物制药公司Mirati Therapeutics, Inc.的董事。他还自2010年1月起担任风险投资公司Pappas Ventures的风险合伙人，于2019年1月至2020年4月担任私营生物制药公司Curzion Pharmaceuticals，Inc.的董事，该公司于2020年4月被Horizon收购，并于2011年9月至2023年10月担任Horizon的董事。Grey先生于2019年1月至2019年9月担任Curzion总裁兼首席执行官，于2015年10月至2017年1月担任Amplyx Pharmaceuticals，Inc.总裁兼首席执行官，并于2014年9月至2017年12月担任Reneo董事长兼首席执行官。2011年2月至2014年6月，Grey先生担任Lumena Pharmaceuticals, Inc.的总裁兼首席执行官，该公司于2014年6月被Shire plc收购。Grey先生在制药和生物技术行业拥有超过45年的经验，曾在多家公司担任高级职务，包括SGX Pharmaceuticals，Inc.（于2008年出售给Eli Lilly and Company）的总裁兼首席执行官、Trega Biosciences，Inc.（于2001年出售给LION Bioscience，Inc.）的总裁兼首席执行官以及BioChem Therapeutic Inc.的总裁。在此之前，Grey先生曾在Glaxo，Inc.和Glaxo Holdings PLC担任多个职务，最终担任公司发展副总裁和国际许可总监。Grey先生在英国Nottingham大学获得化学学士学位。
Michael Grey,has served as Executive Chairman of the Board since April 2017 and served as Spruce Biosciences, Inc. Interim Chief Executive Officer from November 2021 to January 2022. In addition, Mr. Grey has served as Chairman of Mirum Pharmaceuticals, Inc., a public biopharmaceutical company, since January 2020, and has been a director of Mirum since May 2018. Mr. Grey previously served as Executive Chairman of Mirum from March 2019 to December 2019 and Chief Executive Officer of Mirum from May 2018 to March 2019. Mr. Grey served as Executive Chairman of Reneo Pharmaceuticals, Inc. from December 2017 to October 2024 (merged with OnKure, Inc., a biopharmaceutical company, in 2024) and has served as a director for OnKure since October 2024. Mr. Grey has served as Executive Chairman of Plexium since September 2020. He has served as Chairman of Sorriso Pharmaceuticals, Inc., a private pharmaceutical company since May 2021 and as Executive Chair of Theolytics Ltd., a private biotechnology company, since November 2023. Mr. Grey previously served as a director of BioMarin from December 2005 to May 2021 and as director of Mirati Therapeutics, Inc., a biopharmaceutical company, from November 2014 to June 2021. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010, as a director of Curzion Pharmaceuticals, Inc., a private biopharmaceutical company, which was acquired in April 2020 by Horizon, from January 2019 to April 2020, and as a director at Horizon from September 2011 to October 2023. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion, from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001), and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc., and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey received a B.S. in chemistry from the University of Nottingham in the United Kingdom. - Michael Grey，自2017年4月起担任董事会执行主席，并于2021年11月至2022年1月担任Spruce Biosciences, Inc.临时首席执行官。此外，Grey先生自2020年1月起担任上市生物制药公司Mirum Pharmaceuticals, Inc.的董事长，并自2018年5月起担任Mirum的董事。Grey先生此前曾于2019年3月至2019年12月担任Mirum执行主席，并于2018年5月至2019年3月担任Mirum首席执行官。Grey先生于2017年12月至2024年10月担任Reneo Pharmaceuticals，Inc.（于2024年与生物制药公司OnKure，Inc.合并）的执行主席，并自2024年10月起担任OnKure的董事。Grey先生自2020年9月起担任Plexium执行董事长。他自2021年5月起担任私营制药公司Sorriso Pharmaceuticals，Inc.的董事长，并自2023年11月起担任私营生物技术公司Theolytics Ltd.的执行主席。Grey先生此前曾于2005年12月至2021年5月担任BioMarin的董事，并于2014年11月至2021年6月担任生物制药公司Mirati Therapeutics, Inc.的董事。他还自2010年1月起担任风险投资公司Pappas Ventures的风险合伙人，于2019年1月至2020年4月担任私营生物制药公司Curzion Pharmaceuticals，Inc.的董事，该公司于2020年4月被Horizon收购，并于2011年9月至2023年10月担任Horizon的董事。Grey先生于2019年1月至2019年9月担任Curzion总裁兼首席执行官，于2015年10月至2017年1月担任Amplyx Pharmaceuticals，Inc.总裁兼首席执行官，并于2014年9月至2017年12月担任Reneo董事长兼首席执行官。2011年2月至2014年6月，Grey先生担任Lumena Pharmaceuticals, Inc.的总裁兼首席执行官，该公司于2014年6月被Shire plc收购。Grey先生在制药和生物技术行业拥有超过45年的经验，曾在多家公司担任高级职务，包括SGX Pharmaceuticals，Inc.（于2008年出售给Eli Lilly and Company）的总裁兼首席执行官、Trega Biosciences，Inc.（于2001年出售给LION Bioscience，Inc.）的总裁兼首席执行官以及BioChem Therapeutic Inc.的总裁。在此之前，Grey先生曾在Glaxo，Inc.和Glaxo Holdings PLC担任多个职务，最终担任公司发展副总裁和国际许可总监。Grey先生在英国Nottingham大学获得化学学士学位。
- Michael Grey,has served as Executive Chairman of the Board since April 2017 and served as Spruce Biosciences, Inc. Interim Chief Executive Officer from November 2021 to January 2022. In addition, Mr. Grey has served as Chairman of Mirum Pharmaceuticals, Inc., a public biopharmaceutical company, since January 2020, and has been a director of Mirum since May 2018. Mr. Grey previously served as Executive Chairman of Mirum from March 2019 to December 2019 and Chief Executive Officer of Mirum from May 2018 to March 2019. Mr. Grey served as Executive Chairman of Reneo Pharmaceuticals, Inc. from December 2017 to October 2024 (merged with OnKure, Inc., a biopharmaceutical company, in 2024) and has served as a director for OnKure since October 2024. Mr. Grey has served as Executive Chairman of Plexium since September 2020. He has served as Chairman of Sorriso Pharmaceuticals, Inc., a private pharmaceutical company since May 2021 and as Executive Chair of Theolytics Ltd., a private biotechnology company, since November 2023. Mr. Grey previously served as a director of BioMarin from December 2005 to May 2021 and as director of Mirati Therapeutics, Inc., a biopharmaceutical company, from November 2014 to June 2021. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010, as a director of Curzion Pharmaceuticals, Inc., a private biopharmaceutical company, which was acquired in April 2020 by Horizon, from January 2019 to April 2020, and as a director at Horizon from September 2011 to October 2023. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion, from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001), and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc., and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey received a B.S. in chemistry from the University of Nottingham in the United Kingdom.
- Laura Brege
-
Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大学工商管理硕士学位。
Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc., each public companies, and T-knife Therapeutics, Inc., a privately held company. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation, HLS Therapeutics, Inc. and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. - Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大学工商管理硕士学位。
- Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc., each public companies, and T-knife Therapeutics, Inc., a privately held company. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation, HLS Therapeutics, Inc. and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
- Saira Ramasastry
-
Saira Ramasastry，2013年2月起担任董事。2013年之前，她是本公司的顾问。她从2009年起，担任Life Sciences Advisory, LLC的管理合伙人，这是一个生命科学行业的咨询公司。1999-2009，她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998，她是投资银行公司Wasserstein Perella & Co.并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事，是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员，也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位，并在 University of Cambridge获得管理研究的学术硕士学位。
Saira Ramasastry has served as a member of our Board of Directors since March 2021. Ms. Ramasastry is the Managing Partner of Life Sciences Advisory, LLC, since April 2009 a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life sciences industry. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. From August 1999 to March 2009 Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry has served on the boards of directors of Therapeutics Inc., since June 2012 Vir Biotechnology, Inc., since September 2019 Glenmark Pharmaceuticals, Ltd., since April 2019 and Akounos, Inc. since June 2020. Ms. Ramasastry previously served on the boards of directors of Cassava Sciences, Inc., from February 2013 to June 2020 Repros Therapeutics Inc. from March 2013 until it was acquired by Allergan plc in January 2018 and Innovate Biopharmaceuticals, Inc. from June 2018 until it was acquired by RDD Pharma Ltd. in April 2020. Ms. Ramasastry received her B.A. in Economics with honors and distinction and an M.S. in Management Science and Engineering from Stanford University, as well as an M.Phil. in Management Studies from the University of Cambridge where she is a guest lecturer for the Bioscience Enterprise Programme. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. - Saira Ramasastry，2013年2月起担任董事。2013年之前，她是本公司的顾问。她从2009年起，担任Life Sciences Advisory, LLC的管理合伙人，这是一个生命科学行业的咨询公司。1999-2009，她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998，她是投资银行公司Wasserstein Perella & Co.并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事，是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员，也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位，并在 University of Cambridge获得管理研究的学术硕士学位。
- Saira Ramasastry has served as a member of our Board of Directors since March 2021. Ms. Ramasastry is the Managing Partner of Life Sciences Advisory, LLC, since April 2009 a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life sciences industry. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. From August 1999 to March 2009 Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry has served on the boards of directors of Therapeutics Inc., since June 2012 Vir Biotechnology, Inc., since September 2019 Glenmark Pharmaceuticals, Ltd., since April 2019 and Akounos, Inc. since June 2020. Ms. Ramasastry previously served on the boards of directors of Cassava Sciences, Inc., from February 2013 to June 2020 Repros Therapeutics Inc. from March 2013 until it was acquired by Allergan plc in January 2018 and Innovate Biopharmaceuticals, Inc. from June 2018 until it was acquired by RDD Pharma Ltd. in April 2020. Ms. Ramasastry received her B.A. in Economics with honors and distinction and an M.S. in Management Science and Engineering from Stanford University, as well as an M.Phil. in Management Studies from the University of Cambridge where she is a guest lecturer for the Bioscience Enterprise Programme. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.
- Laurent Fischer
-
Laurent Fischer自2017年7月以来一直担任我们的董事之一。Fischer博士自2016年11月被Tobira Therapeutics收购以来，一直担任Allergan（一家全球制药公司）肝脏治疗领域的高级副总裁，主管，自2013年起担任首席执行官。Fischer博士自2017年3月起担任Frazier梦百合Partners生命科学团队的高级顾问。他此前曾担任Jennerex，Inc.（一流的肝癌溶瘤免疫疗法公司，被Sillajen公司以1.5亿美元收购）的主席兼首席执行官。他曾担任Ocera Therapeutics公司的联席创始人、总裁兼首席执行官，也曾担任DuPont-Merck公司、DuPont Pharmaceuticals公司、Hoffmann-La Roche公司的肝脏疾病、病毒学和肿瘤学高级职务。Fischer博士还担任MirumPharmaceuticals，Inc.的董事。Fischer博士在日内瓦大学（University of Geneva）获得本科学位，在瑞士日内瓦医学院（Geneva Medical School，Switzerland）获得医学学位。
Laurent Fischer,has served as a member of the Board since June 2019. Dr. Fischer has served as the President and Chief Executive Officer of Adverum Biotechnologies, Inc., a clinical stage gene therapy company, since June 2020. Prior to Adverum, he served as Senior Vice President, Head of the Liver Therapeutic Area at Allergan plc, a pharmaceutical company, from November 2016 to June 2020. Previously, he served as Chief Executive Officer of Tobira Therapeutics, Inc., a public biotechnology company, until its acquisition by Allergan in November 2016. From 2012 to 2014, Dr. Fischer served as Chairman and Chief Executive Officer of Jennerex Biotherapeutics, Inc. Prior to Jennerex, Dr. Fischer was President and Chief Executive Officer of Ocera Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases, since 2005. Prior to Ocera, Dr. Fischer was President and Chief Executive Officer of life sciences company Auxeris Therapeutics, Inc. from 2003 to 2005, President and Chief Operating Officer of technology company RXCentric.cm, Inc. (now part of Allscripts Healthcare Solutions, Inc.) from 1999 to 2000 and Chief Medical Officer and Vice President of Corporate Development of medication management company MedVantx Inc. from 2001 to 2003. Dr. Fischer served as Senior Vice President of the Global Virology Franchise at Dupont Pharmaceuticals/Dupont-Merck from 1997 to 1999. From 1995 to 1997, Dr. Fischer served as Medical Director for the Virology Group at healthcare company Hoffman-LaRoche, Ltd. Dr. Fischer currently serves on the boards of directors of public biopharmaceutical companies Adverum and CTI BioPharma Corp., where he serves as Chairman, and privately held biopharmaceutical company Lycia Therapeutics, Inc. Dr. Fischer received his Medical Degree from the University of Geneva and his Doctorate in Medicine from the Geneva Medical School, Switzerland. - Laurent Fischer自2017年7月以来一直担任我们的董事之一。Fischer博士自2016年11月被Tobira Therapeutics收购以来，一直担任Allergan（一家全球制药公司）肝脏治疗领域的高级副总裁，主管，自2013年起担任首席执行官。Fischer博士自2017年3月起担任Frazier梦百合Partners生命科学团队的高级顾问。他此前曾担任Jennerex，Inc.（一流的肝癌溶瘤免疫疗法公司，被Sillajen公司以1.5亿美元收购）的主席兼首席执行官。他曾担任Ocera Therapeutics公司的联席创始人、总裁兼首席执行官，也曾担任DuPont-Merck公司、DuPont Pharmaceuticals公司、Hoffmann-La Roche公司的肝脏疾病、病毒学和肿瘤学高级职务。Fischer博士还担任MirumPharmaceuticals，Inc.的董事。Fischer博士在日内瓦大学（University of Geneva）获得本科学位，在瑞士日内瓦医学院（Geneva Medical School，Switzerland）获得医学学位。
- Laurent Fischer,has served as a member of the Board since June 2019. Dr. Fischer has served as the President and Chief Executive Officer of Adverum Biotechnologies, Inc., a clinical stage gene therapy company, since June 2020. Prior to Adverum, he served as Senior Vice President, Head of the Liver Therapeutic Area at Allergan plc, a pharmaceutical company, from November 2016 to June 2020. Previously, he served as Chief Executive Officer of Tobira Therapeutics, Inc., a public biotechnology company, until its acquisition by Allergan in November 2016. From 2012 to 2014, Dr. Fischer served as Chairman and Chief Executive Officer of Jennerex Biotherapeutics, Inc. Prior to Jennerex, Dr. Fischer was President and Chief Executive Officer of Ocera Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases, since 2005. Prior to Ocera, Dr. Fischer was President and Chief Executive Officer of life sciences company Auxeris Therapeutics, Inc. from 2003 to 2005, President and Chief Operating Officer of technology company RXCentric.cm, Inc. (now part of Allscripts Healthcare Solutions, Inc.) from 1999 to 2000 and Chief Medical Officer and Vice President of Corporate Development of medication management company MedVantx Inc. from 2001 to 2003. Dr. Fischer served as Senior Vice President of the Global Virology Franchise at Dupont Pharmaceuticals/Dupont-Merck from 1997 to 1999. From 1995 to 1997, Dr. Fischer served as Medical Director for the Virology Group at healthcare company Hoffman-LaRoche, Ltd. Dr. Fischer currently serves on the boards of directors of public biopharmaceutical companies Adverum and CTI BioPharma Corp., where he serves as Chairman, and privately held biopharmaceutical company Lycia Therapeutics, Inc. Dr. Fischer received his Medical Degree from the University of Geneva and his Doctorate in Medicine from the Geneva Medical School, Switzerland.
- Christopher Peetz
-
Christopher Peetz自2018年4月以来一直担任我们的董事会成员。Peetz先生自2019年3月起担任MirumPharmaceuticals，Inc.总裁兼首席执行官，自2018年11月起担任总裁。自2017年5月以来，他一直担任Frazier梦百合Partners的常驻企业家。他曾于2017年5月至2019年12月担任Flashlight Therapeutics，Inc.的首席执行官，并于2014年5月至2016年12月担任TobiraTherapeutics，Inc.（一家上市生物技术公司，于2016年11月被Allergan plc收购）的首席财务官兼企业发展主管。加入Tobira Therapeutics公司之前，Peetz先生曾担任Jennerex Biotherapeutics公司（一家私营生物制药公司）的Vice President、财务与公司发展部。在加入Jennerex之前，Peetz先生曾在OnyxPharmaceuticals，Inc.（现为Amgen）担任多个职位，包括监督财务规划和分析、公司战略、产品生命周期管理和商业角色。在Onyx之前，Peetz先生在LaSalle Corporate Finance（ABN AMRO的一部分）提供并购咨询服务，并在Abgenix Inc.和Solazyme Inc.担任职位。Peetz先生在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，并在圣路易斯的华盛顿大学（Washington University）获得金融、国际商务与法语的B.S.B.A.。
Christopher Peetz,is Mirum Pharmaceuticals, Inc. co-founder and has served as Mirum Pharmaceuticals, Inc. President since December 2018 and as Mirum Pharmaceuticals, Inc. Chief Executive Officer since March 2019. Mr. Peetz has been an Entrepreneur-in-Residence at Frazier since May 2017. Prior to joining Mirum Pharmaceuticals, Inc. company, Mr. Peetz served as the Chief Executive Officer of Flashlight Therapeutics, Inc., a biotechnology company, from May 2017 to May 2019. From May 2014 to December 2016, Mr. Peetz served as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc., a public biotechnology company acquired by Allergan plc, in November 2016. Prior to joining Tobira, Mr. Peetz served as Vice President, Finance and Corporate Development of Jennerex Biotherapeutics, Inc., a biopharmaceutical company, from April 2012 to March 2014. Prior to Jennerex, Mr. Peetz held various positions at Onyx Pharmaceuticals, Inc., including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He currently serves on the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company. Mr. Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis. - Christopher Peetz自2018年4月以来一直担任我们的董事会成员。Peetz先生自2019年3月起担任MirumPharmaceuticals，Inc.总裁兼首席执行官，自2018年11月起担任总裁。自2017年5月以来，他一直担任Frazier梦百合Partners的常驻企业家。他曾于2017年5月至2019年12月担任Flashlight Therapeutics，Inc.的首席执行官，并于2014年5月至2016年12月担任TobiraTherapeutics，Inc.（一家上市生物技术公司，于2016年11月被Allergan plc收购）的首席财务官兼企业发展主管。加入Tobira Therapeutics公司之前，Peetz先生曾担任Jennerex Biotherapeutics公司（一家私营生物制药公司）的Vice President、财务与公司发展部。在加入Jennerex之前，Peetz先生曾在OnyxPharmaceuticals，Inc.（现为Amgen）担任多个职位，包括监督财务规划和分析、公司战略、产品生命周期管理和商业角色。在Onyx之前，Peetz先生在LaSalle Corporate Finance（ABN AMRO的一部分）提供并购咨询服务，并在Abgenix Inc.和Solazyme Inc.担任职位。Peetz先生在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，并在圣路易斯的华盛顿大学（Washington University）获得金融、国际商务与法语的B.S.B.A.。
- Christopher Peetz,is Mirum Pharmaceuticals, Inc. co-founder and has served as Mirum Pharmaceuticals, Inc. President since December 2018 and as Mirum Pharmaceuticals, Inc. Chief Executive Officer since March 2019. Mr. Peetz has been an Entrepreneur-in-Residence at Frazier since May 2017. Prior to joining Mirum Pharmaceuticals, Inc. company, Mr. Peetz served as the Chief Executive Officer of Flashlight Therapeutics, Inc., a biotechnology company, from May 2017 to May 2019. From May 2014 to December 2016, Mr. Peetz served as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc., a public biotechnology company acquired by Allergan plc, in November 2016. Prior to joining Tobira, Mr. Peetz served as Vice President, Finance and Corporate Development of Jennerex Biotherapeutics, Inc., a biopharmaceutical company, from April 2012 to March 2014. Prior to Jennerex, Mr. Peetz held various positions at Onyx Pharmaceuticals, Inc., including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He currently serves on the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company. Mr. Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.
- Patrick Heron
-
Patrick Heron自2017年3月以来一直担任我们的董事会成员。自1999年8月以来，Heron先生一直担任Frazier梦百合Partners（一家风险投资公司）的管理普通合伙人。Heron先生目前在制药公司Iterum Therapeutics Plc、制药公司MirumPharmaceuticals，Inc.和医学皮肤科公司Arcutis Biotherapeutics的董事会任职，并在几家私营生命科学公司的董事会任职。Heron先生拥有北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）的政治学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Patrick Heron,has served on board of directors since July 2020. He has been a Managing Partner of Frazier's Life Sciences team since August 1999. Prior to that, Mr. Heron helped develop McKinsey & Company's west coast biotechnology consulting practice. He currently serves on the boards of directors of HilleVax, Inc. (Nasdaq: HLVX) since September 2021 and Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) since November 2018, as well as chairman of the board of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) since January 2017. Mr. Heron previously served as chairman of the board of Scout Bio, Inc. from January 2018 to December 2023, and as a director of SanReno Therapeutics from January 2022 to December 2023, Imago Biosciences, Inc. (acquired by Merck & Co., Inc). from October 2014 to May 2022, Vaxcyte, Inc. (Nasdaq: PCVX) from April 2017 to September 2021, Passage Bio, Inc. (Nasdaq: PASG) from July 2018 to June 2021 and Iterum Therapeutics plc (Nasdaq: ITRM) from August 2015 to April 2021. He has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage drug discovery companies to $100M commercial-stage dermatology companies. He received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar. - Patrick Heron自2017年3月以来一直担任我们的董事会成员。自1999年8月以来，Heron先生一直担任Frazier梦百合Partners（一家风险投资公司）的管理普通合伙人。Heron先生目前在制药公司Iterum Therapeutics Plc、制药公司MirumPharmaceuticals，Inc.和医学皮肤科公司Arcutis Biotherapeutics的董事会任职，并在几家私营生命科学公司的董事会任职。Heron先生拥有北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）的政治学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Patrick Heron,has served on board of directors since July 2020. He has been a Managing Partner of Frazier's Life Sciences team since August 1999. Prior to that, Mr. Heron helped develop McKinsey & Company's west coast biotechnology consulting practice. He currently serves on the boards of directors of HilleVax, Inc. (Nasdaq: HLVX) since September 2021 and Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) since November 2018, as well as chairman of the board of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) since January 2017. Mr. Heron previously served as chairman of the board of Scout Bio, Inc. from January 2018 to December 2023, and as a director of SanReno Therapeutics from January 2022 to December 2023, Imago Biosciences, Inc. (acquired by Merck & Co., Inc). from October 2014 to May 2022, Vaxcyte, Inc. (Nasdaq: PCVX) from April 2017 to September 2021, Passage Bio, Inc. (Nasdaq: PASG) from July 2018 to June 2021 and Iterum Therapeutics plc (Nasdaq: ITRM) from August 2015 to April 2021. He has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage drug discovery companies to $100M commercial-stage dermatology companies. He received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.
高管简历
中英对照 | 中文 | 英文- Peter Radovich
Peter Radovich， 他曾一直担任Rain Oncology Inc.的副总裁，负责项目领导和业务策略（2014年11月以来）。此前，他于2006年9月加入Onyx Pharmaceuticals公司（被Amgen公司收购），也曾担任项目领导副总裁（从2014年2月到2014年11月）、高级董事（从2011年8月到2014年2月），期间也曾领导公司的全球跨职能产品团队，负责Kyprolis的开发和商业化。加入Onyx公司之前，他曾任职Chiron Corporation （现称为Novartis AG），负责多种肿瘤适应症的Proleukin（白细胞介素-2）的产品营销支持。他持有Texas Christian University的生物学和化学学士学位，以及圣路易斯华盛顿大学（Washington University in St. Louis）的工商管理硕士学位。
Peter Radovich,has served as Mirum Pharmaceuticals, Inc. Chief Operating Officer since April 2020. Previously, Mr. Radovich worked in various positions at Global Blood Therapeutics, Inc. from November 2014 through April 2020, including as vice president, program leadership and business strategy, senior vice president, operations and executive vice president, operations. During his tenure at Global Blood Therapeutics, Mr. Radovich was responsible for the company's technical operations, supply chain, program management and leadership, quality assurance and commercial strategy and analytics functions. From 2013 to 2014, Mr. Radovich served as Vice President, Global Product Leader – Kyprolis at Onyx Pharmaceuticals, Inc., which was acquired by Amgen, Inc., where he led the company's global, cross-functional product team responsible for the development and commercialization of Kyprolis. Between 2006 and 2013, he held a variety of roles of increasing responsibility in Onyx's commercial organization supporting Kyprolis and Nexavar and was a key member of the deal team for Onyx's acquisition of Proteolix. From 2004 to 2006, Mr. Radovich was at Chiron Corporation (acquired by Novartis AG) in product marketing supporting Proleukin (interleukin-2) in multiple oncology indications. Mr. Radovich received a B.A. in biology and chemistry from Texas Christian University and an MBA from Washington University in St. Louis.- Peter Radovich， 他曾一直担任Rain Oncology Inc.的副总裁，负责项目领导和业务策略（2014年11月以来）。此前，他于2006年9月加入Onyx Pharmaceuticals公司（被Amgen公司收购），也曾担任项目领导副总裁（从2014年2月到2014年11月）、高级董事（从2011年8月到2014年2月），期间也曾领导公司的全球跨职能产品团队，负责Kyprolis的开发和商业化。加入Onyx公司之前，他曾任职Chiron Corporation （现称为Novartis AG），负责多种肿瘤适应症的Proleukin（白细胞介素-2）的产品营销支持。他持有Texas Christian University的生物学和化学学士学位，以及圣路易斯华盛顿大学（Washington University in St. Louis）的工商管理硕士学位。
- Peter Radovich,has served as Mirum Pharmaceuticals, Inc. Chief Operating Officer since April 2020. Previously, Mr. Radovich worked in various positions at Global Blood Therapeutics, Inc. from November 2014 through April 2020, including as vice president, program leadership and business strategy, senior vice president, operations and executive vice president, operations. During his tenure at Global Blood Therapeutics, Mr. Radovich was responsible for the company's technical operations, supply chain, program management and leadership, quality assurance and commercial strategy and analytics functions. From 2013 to 2014, Mr. Radovich served as Vice President, Global Product Leader – Kyprolis at Onyx Pharmaceuticals, Inc., which was acquired by Amgen, Inc., where he led the company's global, cross-functional product team responsible for the development and commercialization of Kyprolis. Between 2006 and 2013, he held a variety of roles of increasing responsibility in Onyx's commercial organization supporting Kyprolis and Nexavar and was a key member of the deal team for Onyx's acquisition of Proteolix. From 2004 to 2006, Mr. Radovich was at Chiron Corporation (acquired by Novartis AG) in product marketing supporting Proleukin (interleukin-2) in multiple oncology indications. Mr. Radovich received a B.A. in biology and chemistry from Texas Christian University and an MBA from Washington University in St. Louis.
- Pamela Vig
Pamela Vig自2018年12月起担任我们的首席科学官。此前，VIG博士于2017年11月起担任Flashlight的首席科学官兼临床负责人。Vig博士于2015年7月至2016年11月被Allergan收购期间担任Tobira的Vice President、临床研究和发现。作为收购Tobira的一部分，她加入Allergan，担任临床研究与开发助理Vice President，直到2017年11月。在加入Tobira之前，Vig博士于2010年1月至2015年7月担任Presidio Pharmaceuticals临床研究Vice President。在Presidio，VIG博士负责优化公司临床试验计划的设计和进行。Vig博士此前还曾担任英国伦敦强生公司全球医疗事务总监，负责HCV和HIV化合物的后期开发和商业化的战略和优化。她也曾担任Idenix Pharmaceuticals公司、Gilead Sciences公司的多种职务。Vig博士获得了哲学硕士学位。以及伦敦帝国理工学院（Imperial College London）肝脏学研究科学系博士学位。
Pamela Vig,has served as Mirum Pharmaceuticals, Inc. Head of Research and Development since November 2021. Previously, Dr. Vig served as Mirum Pharmaceuticals, Inc. Chief Scientific Officer from December 2018 and as Chief Scientific Officer and clinical lead at Flashlight Therapeutics, Inc. from November 2017. Dr. Vig served as Vice President, Clinical Research and Discovery at Tobira Therapeutics, Inc. from July 2015 until its acquisition in November 2016 by Allergan plc. As part of the Tobira acquisition, she joined Allergan as Associate Vice President, Clinical Research and Development, a position she held until November 2017. Prior to joining Tobira, Dr. Vig served as Vice President, Clinical Research for Presidio Pharmaceuticals, from January 2010 to July 2015. At Presidio, Dr. Vig was responsible for optimizing the design and conduct of the company's clinical trial programs. Dr. Vig also previously served as Director, Global Medical Affairs, at Johnson & Johnson in London, United Kingdom, where she was responsible for the strategy and optimization of late-stage development and commercialization of HCV and HIV compounds. She has also held various positions at Idenix Pharmaceuticals and Gilead Sciences. Dr. Vig received a M.Phil. and a Ph.D. from Imperial College London from the Department of Hepatology in Investigative Science.- Pamela Vig自2018年12月起担任我们的首席科学官。此前，VIG博士于2017年11月起担任Flashlight的首席科学官兼临床负责人。Vig博士于2015年7月至2016年11月被Allergan收购期间担任Tobira的Vice President、临床研究和发现。作为收购Tobira的一部分，她加入Allergan，担任临床研究与开发助理Vice President，直到2017年11月。在加入Tobira之前，Vig博士于2010年1月至2015年7月担任Presidio Pharmaceuticals临床研究Vice President。在Presidio，VIG博士负责优化公司临床试验计划的设计和进行。Vig博士此前还曾担任英国伦敦强生公司全球医疗事务总监，负责HCV和HIV化合物的后期开发和商业化的战略和优化。她也曾担任Idenix Pharmaceuticals公司、Gilead Sciences公司的多种职务。Vig博士获得了哲学硕士学位。以及伦敦帝国理工学院（Imperial College London）肝脏学研究科学系博士学位。
- Pamela Vig,has served as Mirum Pharmaceuticals, Inc. Head of Research and Development since November 2021. Previously, Dr. Vig served as Mirum Pharmaceuticals, Inc. Chief Scientific Officer from December 2018 and as Chief Scientific Officer and clinical lead at Flashlight Therapeutics, Inc. from November 2017. Dr. Vig served as Vice President, Clinical Research and Discovery at Tobira Therapeutics, Inc. from July 2015 until its acquisition in November 2016 by Allergan plc. As part of the Tobira acquisition, she joined Allergan as Associate Vice President, Clinical Research and Development, a position she held until November 2017. Prior to joining Tobira, Dr. Vig served as Vice President, Clinical Research for Presidio Pharmaceuticals, from January 2010 to July 2015. At Presidio, Dr. Vig was responsible for optimizing the design and conduct of the company's clinical trial programs. Dr. Vig also previously served as Director, Global Medical Affairs, at Johnson & Johnson in London, United Kingdom, where she was responsible for the strategy and optimization of late-stage development and commercialization of HCV and HIV compounds. She has also held various positions at Idenix Pharmaceuticals and Gilead Sciences. Dr. Vig received a M.Phil. and a Ph.D. from Imperial College London from the Department of Hepatology in Investigative Science.
- Lara Longpre
Lara Longpre自2018年12月起担任我们的首席开发官，领导我们的开发运营，项目管理和联盟管理。此前，Longpre女士于2017年11月起担任Flashlight首席运营官。2014年9月至2018年6月，Longpre女士担任生物制药公司MedGenesis Therapeutix Inc.的首席运营官，负责项目管理，联盟管理，临床运营，技术运营和业务运营。在此之前，Longpre女士于2008年4月至2015年5月在Jennerex担任多个职位，包括2010年7月至2014年5月担任首席运营官。加入Jennerex公司之前，她曾担任MedGenesis公司的高级副总裁，负责临床和公司事务，在那里她曾负责业务运营，包括知识产权投资组合、公司文件和运营计划。她此前也曾担任PRA International公司和Cromedica公司的多种领导职务，包括运营、监管事务、提案和合同。Longpre女士在康奈尔大学（Cornell University）获得生物学学士学位，在哈佛医学院（Harvard Medical School）获得硕士学位，并在加拿大安大略省皇后大学（Queen&8217；s University）获得工商管理硕士学位。
Lara Longpre,has served as Mirum Pharmaceuticals, Inc. Chief Development Officer since December 2018, where she leads Mirum Pharmaceuticals, Inc. development operations, program management and alliance management. Previously, Ms. Longpre served as Chief Operating Officer at Flashlight Therapeutics, Inc. from November 2017. From September 2014 to June 2018, Ms. Longpre served as Chief Operating Officer of MedGenesis Therapeutix Inc., a biopharmaceutical company, where she was responsible for program management, alliance management, clinical operations, technical operations, and business operations. Prior to that, Ms. Longpre held multiple positions at Jennerex Biotherapeutics, Inc. from April 2008 to May 2015, including Chief Operating Officer from July 2010 to May 2014. Before joining Jennerex, Ms. Longpre was Senior Vice-President, Clinical and Corporate Affairs at MedGenesis, where she was responsible for business operations including the intellectual property portfolio, corporate files and operating plans. She also previously held several leadership roles with PRA International and CroMedica including operations, regulatory affairs, and proposals and contracts. Ms. Longpre received a B.A. in biology from Cornell University, a M.M.S. from Harvard Medical School and an MBA from Queen's University in Ontario, Canada.- Lara Longpre自2018年12月起担任我们的首席开发官，领导我们的开发运营，项目管理和联盟管理。此前，Longpre女士于2017年11月起担任Flashlight首席运营官。2014年9月至2018年6月，Longpre女士担任生物制药公司MedGenesis Therapeutix Inc.的首席运营官，负责项目管理，联盟管理，临床运营，技术运营和业务运营。在此之前，Longpre女士于2008年4月至2015年5月在Jennerex担任多个职位，包括2010年7月至2014年5月担任首席运营官。加入Jennerex公司之前，她曾担任MedGenesis公司的高级副总裁，负责临床和公司事务，在那里她曾负责业务运营，包括知识产权投资组合、公司文件和运营计划。她此前也曾担任PRA International公司和Cromedica公司的多种领导职务，包括运营、监管事务、提案和合同。Longpre女士在康奈尔大学（Cornell University）获得生物学学士学位，在哈佛医学院（Harvard Medical School）获得硕士学位，并在加拿大安大略省皇后大学（Queen&8217；s University）获得工商管理硕士学位。
- Lara Longpre,has served as Mirum Pharmaceuticals, Inc. Chief Development Officer since December 2018, where she leads Mirum Pharmaceuticals, Inc. development operations, program management and alliance management. Previously, Ms. Longpre served as Chief Operating Officer at Flashlight Therapeutics, Inc. from November 2017. From September 2014 to June 2018, Ms. Longpre served as Chief Operating Officer of MedGenesis Therapeutix Inc., a biopharmaceutical company, where she was responsible for program management, alliance management, clinical operations, technical operations, and business operations. Prior to that, Ms. Longpre held multiple positions at Jennerex Biotherapeutics, Inc. from April 2008 to May 2015, including Chief Operating Officer from July 2010 to May 2014. Before joining Jennerex, Ms. Longpre was Senior Vice-President, Clinical and Corporate Affairs at MedGenesis, where she was responsible for business operations including the intellectual property portfolio, corporate files and operating plans. She also previously held several leadership roles with PRA International and CroMedica including operations, regulatory affairs, and proposals and contracts. Ms. Longpre received a B.A. in biology from Cornell University, a M.M.S. from Harvard Medical School and an MBA from Queen's University in Ontario, Canada.
- Peter Radovich
Peter Radovich，自2020年4月起担任Mirum Pharmaceuticals, Inc.首席运营官。在此之前，Radovich先生曾于2014年11月至2020年4月在全球血液疗法公司担任多个职位，包括副总裁、项目领导和业务战略、高级副总裁、运营和执行副总裁、运营。在全球血液疗法任职期间，Radovich先生负责公司的技术运营、供应链、项目管理和领导、质量保证以及商业战略和分析职能。2013年至2014年，Radovich先生在被安进收购的奥尼斯医药担任副总裁兼全球产品负责人– Kyprolis，在那里他领导公司的全球性跨职能产品团队，负责Kyprolis 的开发和商业化。在2006年至2013年期间，他在Onyx支持Kyprolis和Nexavar 的商业组织中担任了越来越多的角色，并且是Onyx收购Proteolix交易团队的关键成员。从2004年到2006年，Radovich先生在Chiron Corporation（被诺华公司收购）从事支持Proleukin （interleukin-2）在多个肿瘤适应症中的产品营销工作。Radovich先生获得了得克萨斯基督教大学的生物和化学学士学位以及圣路易斯华盛顿大学的MBA学位。
Peter Radovich,has served as Mirum Pharmaceuticals, Inc. Chief Operating Officer since April 2020. Previously, Mr. Radovich worked in various positions at Global Blood Therapeutics, Inc. from November 2014 through April 2020, including as vice president, program leadership and business strategy, senior vice president, operations and executive vice president, operations. During his tenure at Global Blood Therapeutics, Mr. Radovich was responsible for the company's technical operations, supply chain, program management and leadership, quality assurance and commercial strategy and analytics functions. From 2013 to 2014, Mr. Radovich served as Vice President, Global Product Leader – Kyprolis at Onyx Pharmaceuticals, Inc., which was acquired by Amgen, Inc., where he led the company's global, cross-functional product team responsible for the development and commercialization of Kyprolis. Between 2006 and 2013, he held a variety of roles of increasing responsibility in Onyx's commercial organization supporting Kyprolis and Nexavar and was a key member of the deal team for Onyx's acquisition of Proteolix. From 2004 to 2006, Mr. Radovich was at Chiron Corporation (acquired by Novartis AG) in product marketing supporting Proleukin (interleukin-2) in multiple oncology indications. Mr. Radovich received a B.A. in biology and chemistry from Texas Christian University and an MBA from Washington University in St. Louis.- Peter Radovich，自2020年4月起担任Mirum Pharmaceuticals, Inc.首席运营官。在此之前，Radovich先生曾于2014年11月至2020年4月在全球血液疗法公司担任多个职位，包括副总裁、项目领导和业务战略、高级副总裁、运营和执行副总裁、运营。在全球血液疗法任职期间，Radovich先生负责公司的技术运营、供应链、项目管理和领导、质量保证以及商业战略和分析职能。2013年至2014年，Radovich先生在被安进收购的奥尼斯医药担任副总裁兼全球产品负责人– Kyprolis，在那里他领导公司的全球性跨职能产品团队，负责Kyprolis 的开发和商业化。在2006年至2013年期间，他在Onyx支持Kyprolis和Nexavar 的商业组织中担任了越来越多的角色，并且是Onyx收购Proteolix交易团队的关键成员。从2004年到2006年，Radovich先生在Chiron Corporation（被诺华公司收购）从事支持Proleukin （interleukin-2）在多个肿瘤适应症中的产品营销工作。Radovich先生获得了得克萨斯基督教大学的生物和化学学士学位以及圣路易斯华盛顿大学的MBA学位。
- Peter Radovich,has served as Mirum Pharmaceuticals, Inc. Chief Operating Officer since April 2020. Previously, Mr. Radovich worked in various positions at Global Blood Therapeutics, Inc. from November 2014 through April 2020, including as vice president, program leadership and business strategy, senior vice president, operations and executive vice president, operations. During his tenure at Global Blood Therapeutics, Mr. Radovich was responsible for the company's technical operations, supply chain, program management and leadership, quality assurance and commercial strategy and analytics functions. From 2013 to 2014, Mr. Radovich served as Vice President, Global Product Leader – Kyprolis at Onyx Pharmaceuticals, Inc., which was acquired by Amgen, Inc., where he led the company's global, cross-functional product team responsible for the development and commercialization of Kyprolis. Between 2006 and 2013, he held a variety of roles of increasing responsibility in Onyx's commercial organization supporting Kyprolis and Nexavar and was a key member of the deal team for Onyx's acquisition of Proteolix. From 2004 to 2006, Mr. Radovich was at Chiron Corporation (acquired by Novartis AG) in product marketing supporting Proleukin (interleukin-2) in multiple oncology indications. Mr. Radovich received a B.A. in biology and chemistry from Texas Christian University and an MBA from Washington University in St. Louis.
- Christopher Peetz
Christopher Peetz自2018年4月以来一直担任我们的董事会成员。Peetz先生自2019年3月起担任MirumPharmaceuticals，Inc.总裁兼首席执行官，自2018年11月起担任总裁。自2017年5月以来，他一直担任Frazier梦百合Partners的常驻企业家。他曾于2017年5月至2019年12月担任Flashlight Therapeutics，Inc.的首席执行官，并于2014年5月至2016年12月担任TobiraTherapeutics，Inc.（一家上市生物技术公司，于2016年11月被Allergan plc收购）的首席财务官兼企业发展主管。加入Tobira Therapeutics公司之前，Peetz先生曾担任Jennerex Biotherapeutics公司（一家私营生物制药公司）的Vice President、财务与公司发展部。在加入Jennerex之前，Peetz先生曾在OnyxPharmaceuticals，Inc.（现为Amgen）担任多个职位，包括监督财务规划和分析、公司战略、产品生命周期管理和商业角色。在Onyx之前，Peetz先生在LaSalle Corporate Finance（ABN AMRO的一部分）提供并购咨询服务，并在Abgenix Inc.和Solazyme Inc.担任职位。Peetz先生在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，并在圣路易斯的华盛顿大学（Washington University）获得金融、国际商务与法语的B.S.B.A.。
Christopher Peetz,is Mirum Pharmaceuticals, Inc. co-founder and has served as Mirum Pharmaceuticals, Inc. President since December 2018 and as Mirum Pharmaceuticals, Inc. Chief Executive Officer since March 2019. Mr. Peetz has been an Entrepreneur-in-Residence at Frazier since May 2017. Prior to joining Mirum Pharmaceuticals, Inc. company, Mr. Peetz served as the Chief Executive Officer of Flashlight Therapeutics, Inc., a biotechnology company, from May 2017 to May 2019. From May 2014 to December 2016, Mr. Peetz served as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc., a public biotechnology company acquired by Allergan plc, in November 2016. Prior to joining Tobira, Mr. Peetz served as Vice President, Finance and Corporate Development of Jennerex Biotherapeutics, Inc., a biopharmaceutical company, from April 2012 to March 2014. Prior to Jennerex, Mr. Peetz held various positions at Onyx Pharmaceuticals, Inc., including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He currently serves on the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company. Mr. Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.- Christopher Peetz自2018年4月以来一直担任我们的董事会成员。Peetz先生自2019年3月起担任MirumPharmaceuticals，Inc.总裁兼首席执行官，自2018年11月起担任总裁。自2017年5月以来，他一直担任Frazier梦百合Partners的常驻企业家。他曾于2017年5月至2019年12月担任Flashlight Therapeutics，Inc.的首席执行官，并于2014年5月至2016年12月担任TobiraTherapeutics，Inc.（一家上市生物技术公司，于2016年11月被Allergan plc收购）的首席财务官兼企业发展主管。加入Tobira Therapeutics公司之前，Peetz先生曾担任Jennerex Biotherapeutics公司（一家私营生物制药公司）的Vice President、财务与公司发展部。在加入Jennerex之前，Peetz先生曾在OnyxPharmaceuticals，Inc.（现为Amgen）担任多个职位，包括监督财务规划和分析、公司战略、产品生命周期管理和商业角色。在Onyx之前，Peetz先生在LaSalle Corporate Finance（ABN AMRO的一部分）提供并购咨询服务，并在Abgenix Inc.和Solazyme Inc.担任职位。Peetz先生在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，并在圣路易斯的华盛顿大学（Washington University）获得金融、国际商务与法语的B.S.B.A.。
- Christopher Peetz,is Mirum Pharmaceuticals, Inc. co-founder and has served as Mirum Pharmaceuticals, Inc. President since December 2018 and as Mirum Pharmaceuticals, Inc. Chief Executive Officer since March 2019. Mr. Peetz has been an Entrepreneur-in-Residence at Frazier since May 2017. Prior to joining Mirum Pharmaceuticals, Inc. company, Mr. Peetz served as the Chief Executive Officer of Flashlight Therapeutics, Inc., a biotechnology company, from May 2017 to May 2019. From May 2014 to December 2016, Mr. Peetz served as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc., a public biotechnology company acquired by Allergan plc, in November 2016. Prior to joining Tobira, Mr. Peetz served as Vice President, Finance and Corporate Development of Jennerex Biotherapeutics, Inc., a biopharmaceutical company, from April 2012 to March 2014. Prior to Jennerex, Mr. Peetz held various positions at Onyx Pharmaceuticals, Inc., including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He currently serves on the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company. Mr. Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.